Financials
Financial year 2025
Gross margin
€ 287,023
▲ 1% vs 2024
Profit
Growing€ 213,458
▲ 5% vs 2024
Debts
Low€ 236,794
▲ 24% vs 2024
b+pharma Belgium from Gent, company number BE0474817869, closed financial year 2025 with a result of € 213,458 after tax. For that financial year b+pharma Belgium recorded a gross margin of € 287,023 and equity of € 2.2 million. Compared with financial year 2024, the result moved from € 203,195 to € 213,458. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 4, 2026.
What happened at b+pharma Belgium?
What happened at b+pharma Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- AQUITANIA BV stepped down as director. NBB
- CREDOPHAR BV stepped down as director. NBB
- FARMAFENDER BV stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 213,458 (▲ 5% vs 2024). Source: NBB ↗
- AQUITANIA BV became a director. NBB
- CREDOPHAR BV became a director. NBB
- FARMAFENDER BV became a director. NBB
- New establishment in Gent. KBO
In short
From € 162,791 profit in 2021 to € 213,458 profit in 2025.
Paid € 258,450 in corporate taxes since 2021.
Best year ever: 2022, with € 416,943 profit.
On average € 340,400 of value added per employee in 2022.
A new publication or filing at b+pharma Belgium? We notify you, reason included.
Follow b+pharma BelgiumNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Director · represented by ANJA IMSCHOOT
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, DGPharma +6 more
since 2022 · until 2028
since 2022 · until 2028
since 2022 · until 2028
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
Ceres Pharmaceuticals same network
€ 14.6 million revenue · 2025
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
DGPharma same network
€ 94,120 gross margin · 2024
Ceres Pharma
€ 35.3 million revenue · 2025
+15 more
Details
- Company number
- 0474.817.869
- VAT number
- BE 0474.817.869
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- b+pharma Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 May 2001
- Peppol
- Active · Active since 1 Aug 2025
- Activities · NACE
Handelsbemiddeling in de groothandel in andere specifieke goederen
Groothandel in farmaceutische en medische artikelen
Groothandel in voedsel voor huisdieren
Groothandel in andere voedingsmiddelen, neg
Handelsbemiddeling in de niet-gespecialiseerde groothandel